Command Palette

Search for a command to run...

Clinical Trials · NCT03689374

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

CompletedPhase 3Semaglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
2,274
Start date
Oct 2018
Locations
210 sites, 21 countries
Primary endpoint
Change From Baseline in Glycated Haemoglobin (HbA1c)
View Semaglutide compound reference